Capricor治療 CAPR 深 滬
等待開盤 08-15 09:30:00 美东时间
7.94
-0.360
-4.34%
華盛通- 最 高8.305
- 今 開8.23
- 成交量 42.53万股
- 最 低 7.8101
- 昨 收 8.30
- 總市值 3.63亿
- 52周最高 23.40
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 3.98
- 委 比 -99.34%
- 總股本 4570.78万
- 歷史最高 171.50
- 量 比 0.51
- 振 幅 5.96%
- 歷史最低 0.88
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Capricor Therapeutics Q2 EPS $(0.57) Misses $(0.46) Estimate
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.46) by 23.11 percent. This is a 62.86 percent decrease over losses of $(0.35) per
08-12 05:24
C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around...
08-11 20:45
FDA争议官员回归引爆抛售潮！美股生物科技板块盘前下挫
周一美股盘前，多家生物科技公司股价出现下跌。此前有报道称，曾被解职的美国食品药品监督管理局(FDA)疫苗监管官员Vinay Prasad将重返该机构。
08-11 19:42
Biotech sector slips amid reported return of ousted FDA official
Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency. Prasad, who had o...
08-11 18:25
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
<p>Capricor Therapeutics has postponed its Q2 2025 financial results release to August 11, 2025, due to a scheduled FDA meeting about its Deramiocel therapy for DMD-associated cardiomyopathy. A webcast and conference call will review financials and provide updates at 4:30 p.m. ET on August 11.</p>
08-08 12:30
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
<p>Capricor Therapeutics will release its second quarter 2025 financial results on August 13, 2025, followed by a conference call and webcast at 4:30 p.m. ET. The call can be accessed via toll-free (1-800-717-1738) or international numbers (1-646-307-1865), conference ID 90328, or via the provided webcast link. Additional details about the company and its pipeline, including Deramiocel for Duchenne Muscular Dystrophy, are available on its website...
08-06 13:00
美股牛股 | FDA人事变动或缓解监管压力，REPL飙涨超101%；SUPX大涨44%
FDA人事变动或缓解监管压力，REPL飙涨超101%；推出英伟达Blackwell架构AI服务器，SUPX大涨44%>>
07-31 14:30
Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs
Sarepta Therapeutics (NASDAQ:SRPT), Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics division, recently witnessed sharp increa...
07-30 22:27
